RICCI, ANGELA DALIA
RICCI, ANGELA DALIA
Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: A systematic review and meta-analysis
2020-01-01 Rizzo A.; Frega G.; Ricci A.D.; Palloni A.; Abbati F.; de Lorenzo S.; Deserti M.; Tavolari S.; Brandi G.
Assessment of the Risk of Nodal Involvement in Rectal Neuroendocrine Neoplasms: The NOVARA Score, a Multicentre Retrospective Study
2022-01-01 Ricci A.D.; Pusceddu S.; Panzuto F.; Gelsomino F.; Massironi S.; De Angelis C.G.; Modica R.; Ricco G.; Torchio M.; Rinzivillo M.; Prinzi N.; Rizzi F.; Lamberti G.; Campana D.
Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
2021-01-01 Rizzo A.; Ricci A.D.; Brandi G.
Circulating tumor DNA in biliary tract cancer: Current evidence and future perspectives
2020-01-01 Rizzo A.; Ricci A.D.; Tavolari S.; Brandi G.
Combination therapy of dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer
2021-01-01 Rizzo A.; Ricci A.D.; Brandi G.
Combining immune checkpoint inhibitors with locoregional therapies in hepatocellular carcinoma
2022-01-01 Rizzo A.; Ricci A.D.; Brandi G.
Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: A meta-analysis
2021-01-01 Rizzo A.; Mollica V.; Santoni M.; Rosellini M.; Marchetti A.; Ricci A.D.; Grilli G.; Greco A.; Montironi R.; Ardizzoni A.; Massari F.
Detecting and targeting NTRK gene fusions in cholangiocarcinoma: news and perspectives
2021-01-01 Rizzo A.; Ricci A.D.; Brandi G.
The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): A new Pandora's box?
2020-01-01 Ricci A.D.; Rizzo A.; Brandi G.
Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis
2020-01-01 Alessandro Rizzo; Margherita Nannini; Marco Novelli; Angela Dalia Ricci; Valerio Di Scioscio; Maria Abbondanza Pantaleo
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?
2022-01-01 Riccardo Carloni, Alessandro Rizzo, Angela Dalia Ricci, Giorgio Frega, Alessandro Di Federico, Andrea Palloni, Mariacristina Di Marco, Gennaro Gadaleta-Caldarola, Giovanni Brandi
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer
2021-01-01 Rizzo A.; Ricci A.D.; Brandi G.
The (Eternal) Debate on Microwave Ablation Versus Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma
2020-01-01 Ricci A.D.; Rizzo A.; Bonucci C.; Tavolari S.; Palloni A.; Frega G.; Mollica V.; Tober N.; Mazzotta E.; Felicani C.; Serra C.; Brandi G.
Experimental HER2- targeted therapies for biliary tract cancer
2021-01-01 Rizzo A.; Ricci A.D.; Bonucci C.; Tober N.; Palloni A.; Frega G.; Brandi G.
Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials
2021-01-01 Rizzo A.; Mollica V.; Rosellini M.; Marchetti A.; Ricci A.D.; Fiorentino M.; Battelli N.; Santoni M.; Massari F.
FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue
2021-01-01 Rizzo A.; Ricci A.D.; Frega G.; Di Federico A.; Brandi G.
First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges
2021-01-01 Rizzo A.; Ricci A.D.; Gadaleta-Caldarola G.; Brandi G.
The functioning side of the pancreas: a review on insulinomas
2020-01-01 Maggio I.; Mollica V.; Brighi N.; Lamberti G.; Manuzzi L.; Ricci A.D.; Campana D.
Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives
2021-01-01 Rizzo A.; Ricci A.D.; Brandi G.
Hacking pancreatic cancer: Present and future of personalized medicine
2021-01-01 Di Federico A.; Tateo V.; Parisi C.; Formica F.; Carloni R.; Frega G.; Rizzo A.; Ricci D.; Di Marco M.; Palloni A.; Brandi G.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: A systematic review and meta-analysis | Rizzo A.; Frega G.; Ricci A.D.; Palloni A.; Abbati F.; de Lorenzo S.; Deserti M.; Tavolari S.; Brandi G. | 2020-01-01 | IN VIVO | - | 1.01 Articolo in rivista | - |
| Assessment of the Risk of Nodal Involvement in Rectal Neuroendocrine Neoplasms: The NOVARA Score, a Multicentre Retrospective Study | Ricci A.D.; Pusceddu S.; Panzuto F.; Gelsomino F.; Massironi S.; De Angelis C.G.; Modica R.; Ricco G.; Torchio M.; Rinzivillo M.; Prinzi N.; Rizzi F.; Lamberti G.; Campana D. | 2022-01-01 | JOURNAL OF CLINICAL MEDICINE | - | 1.01 Articolo in rivista | jcm-11-00713-v2.pdf |
| Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma | Rizzo A.; Ricci A.D.; Brandi G. | 2021-01-01 | LIVER CANCER | - | 1.01 Articolo in rivista | - |
| Circulating tumor DNA in biliary tract cancer: Current evidence and future perspectives | Rizzo A.; Ricci A.D.; Tavolari S.; Brandi G. | 2020-01-01 | CANCER GENOMICS & PROTEOMICS. | - | 1.01 Articolo in rivista | - |
| Combination therapy of dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer | Rizzo A.; Ricci A.D.; Brandi G. | 2021-01-01 | HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL | - | 1.04 Replica / breve intervento (e simili) | - |
| Combining immune checkpoint inhibitors with locoregional therapies in hepatocellular carcinoma | Rizzo A.; Ricci A.D.; Brandi G. | 2022-01-01 | EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT | - | 1.01 Articolo in rivista | - |
| Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: A meta-analysis | Rizzo A.; Mollica V.; Santoni M.; Rosellini M.; Marchetti A.; Ricci A.D.; Grilli G.; Greco A.; Montironi R.; Ardizzoni A.; Massari F. | 2021-01-01 | IMMUNOTHERAPY | - | 1.01 Articolo in rivista | - |
| Detecting and targeting NTRK gene fusions in cholangiocarcinoma: news and perspectives | Rizzo A.; Ricci A.D.; Brandi G. | 2021-01-01 | EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT | - | 1.01 Articolo in rivista | - |
| The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): A new Pandora's box? | Ricci A.D.; Rizzo A.; Brandi G. | 2020-01-01 | ESMO OPEN | - | 1.01 Articolo in rivista | - |
| Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis | Alessandro Rizzo; Margherita Nannini; Marco Novelli; Angela Dalia Ricci; Valerio Di Scioscio; Maria Abbondanza Pantaleo | 2020-01-01 | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | - | 1.01 Articolo in rivista | 1758835920936932.pdf |
| Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand? | Riccardo Carloni, Alessandro Rizzo, Angela Dalia Ricci, Giorgio Frega, Alessandro Di Federico, Andrea Palloni, Mariacristina Di Marco, Gennaro Gadaleta-Caldarola, Giovanni Brandi | 2022-01-01 | FUTURE ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer | Rizzo A.; Ricci A.D.; Brandi G. | 2021-01-01 | EXPERT OPINION ON INVESTIGATIONAL DRUGS | - | 1.01 Articolo in rivista | - |
| The (Eternal) Debate on Microwave Ablation Versus Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma | Ricci A.D.; Rizzo A.; Bonucci C.; Tavolari S.; Palloni A.; Frega G.; Mollica V.; Tober N.; Mazzotta E.; Felicani C.; Serra C.; Brandi G. | 2020-01-01 | IN VIVO | - | 1.01 Articolo in rivista | - |
| Experimental HER2- targeted therapies for biliary tract cancer | Rizzo A.; Ricci A.D.; Bonucci C.; Tober N.; Palloni A.; Frega G.; Brandi G. | 2021-01-01 | EXPERT OPINION ON INVESTIGATIONAL DRUGS | - | 1.01 Articolo in rivista | - |
| Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials | Rizzo A.; Mollica V.; Rosellini M.; Marchetti A.; Ricci A.D.; Fiorentino M.; Battelli N.; Santoni M.; Massari F. | 2021-01-01 | PATHOLOGY RESEARCH AND PRACTICE | - | 1.01 Articolo in rivista | - |
| FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue | Rizzo A.; Ricci A.D.; Frega G.; Di Federico A.; Brandi G. | 2021-01-01 | EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY | - | 1.01 Articolo in rivista | - |
| First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges | Rizzo A.; Ricci A.D.; Gadaleta-Caldarola G.; Brandi G. | 2021-01-01 | EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY | - | 1.01 Articolo in rivista | - |
| The functioning side of the pancreas: a review on insulinomas | Maggio I.; Mollica V.; Brighi N.; Lamberti G.; Manuzzi L.; Ricci A.D.; Campana D. | 2020-01-01 | JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION | - | 1.01 Articolo in rivista | - |
| Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives | Rizzo A.; Ricci A.D.; Brandi G. | 2021-01-01 | EXPERT OPINION ON INVESTIGATIONAL DRUGS | - | 1.01 Articolo in rivista | - |
| Hacking pancreatic cancer: Present and future of personalized medicine | Di Federico A.; Tateo V.; Parisi C.; Formica F.; Carloni R.; Frega G.; Rizzo A.; Ricci D.; Di Marco M.; Palloni A.; Brandi G. | 2021-01-01 | PHARMACEUTICALS | - | 1.01 Articolo in rivista | - |